Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective serotonin reuptake inhibition in advanced gastroesophageal cancer receiving immunochemotherapy
2024-518631-11-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sertraline in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Medical University of Vienna. Primary endpoint: Best objective response rate (CR + PR) per RECIST 1.1. Planned start Apr 2023; status: authorised.
02
Drugs
sertraline
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2024-518631-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518631-11-00.